Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The primary endpoint for this study is the clinical response after 12 weeks of treatment,
defined as a change in total score from baseline depressive symptoms as measured by the Beck
Depression Inventory-Amended (BDI-IA) total score.
Phase:
Phase 4
Details
Lead Sponsor:
Lundbeck Italia S.p.A.
Collaborators:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries